Search across all uploaded documents in the knowledge base
Knowledge Explorer
Browse 39 curated topics across 6 categories.
Market Landscape
Competitive analysis of the U.S. peptide and GLP-1 telehealth market
Hims & Hers, Ro, Noom, WeightWatchers, Mochi Health — the weight-loss telehealth boom
Nava Health, Aspire Health, Ways2Well, Regenics — specialized peptide therapy providers
AgelessRx, NADclinic, Joi+Blokes — the longevity medicine and anti-aging space
Research peptide sellers, regulatory risks, and FDA enforcement actions
503A vs 503B pharmacy models serving the telehealth peptide ecosystem
FDA-approved branded drugs versus compounded alternatives — pricing, access, and positioning
Peptide Science
Foundational pharmacology, mechanisms, and drug modality
Definition, drug modality overview, and why 80+ peptide drugs are in clinical use today
Receptor agonism, antagonism, hormone replacement, and target specificity
Half-lives, protease degradation, delivery challenges, and formulation science
Subcutaneous injection, oral delivery, transdermal, microneedles, and iontophoresis
Class-specific safety considerations, boxed warnings, and adverse effects
Clinical Families
Major therapeutic peptide families and their clinical applications
The foundational peptide therapy for diabetes management
GLP-1 receptor agonists, dual GIP/GLP-1 agonists including semaglutide and tirzepatide
Octreotide and related compounds for neuroendocrine tumors and acromegaly
Leuprolide, degarelix for prostate cancer, endometriosis, and precocious puberty
Desmopressin for diabetes insipidus and nocturnal enuresis
Teriparatide for osteoporosis treatment and bone metabolism
Dasiglucagon and glucagon for acute hypoglycemia rescue
Linaclotide for IBS-C and chronic idiopathic constipation
177Lu-DOTATATE and targeted radioligand approaches in neuroendocrine tumors
Peptide Monographs
Detailed drug profiles for individual peptide therapeutics
Ozempic, Wegovy, Rybelsus — the blockbuster GLP-1 agonist for diabetes and obesity
Mounjaro, Zepbound — the dual GIP/GLP-1 agonist redefining metabolic treatment
Body Protection Compound — investigational peptide with tissue repair claims
Immune-modulating peptide with hepatitis and immunodeficiency applications
GHRH analog — historically FDA-approved for GH deficiency diagnostics
FDA-approved GHRH analog for HIV-associated lipodystrophy (Egrifta)
Compounded combination for GH release — regulatory and safety concerns
Melanocortin receptor agonist for hypoactive sexual desire disorder
AOD-9604, GHK-Cu, Epithalon, Kisspeptin-10, Selank, Semax, DSIP, MOTs-C, SS-31, Melanotan II
Regulatory Landscape
503A compounding, FDA guidance, and regulatory frameworks
Bulk drug substance requirements, USP/NF monographs, and FDA bulks list
FDA rules on when compounded drugs too closely replicate commercial products
Why biologics are not eligible for traditional compounding pathways
January 2025 tightening of compounding rules and semaglutide shortage resolution
Sterile vs nonsterile compounding, API characterization, and impurity profiling
Research Frontiers
Cutting-edge peptide research and next-generation therapeutics
SNAC enhancers, permeation enhancers, and the quest for oral peptide drugs
Survodutide, retatrutide, CagriSema — next-gen multi-target metabolic drugs
Depot injections, implants, PEGylation, and extended-release peptide technologies
Targeted delivery using peptides as homing devices for therapeutic payloads
Retatrutide, petrelintide, amycretin — promising pipeline candidates